Alpha-fetoprotein: A renaissance

Tumor Biology

Volumn 34, Issue 4, 2013, Pages 2075-2091

  Terentiev, A A ^a   Moldogazieva, N T ^a  

^a PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

AFP; Alpha fetoprotein; Biologically active peptides; Hepatocellular carcinoma; Onco biomarker; Structure and function

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; DOXORUBICIN; PACLITAXEL;

ALPHA FETOPROTEIN GENE; APOPTOSIS; CANCER GROWTH; CANCER PROGNOSIS; CELL PROLIFERATION; CONFORMATIONAL TRANSITION; DIFFERENTIAL DIAGNOSIS; EMBRYO DEVELOPMENT; HUMAN; IMMUNOMODULATION; LIVER CELL CARCINOMA; METASTASIS; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; PROTEOMICS; PROTO ONCOGENE; REVIEW; SIGNAL TRANSDUCTION; SPINAL DYSRAPHISM;

EID: 84881479095     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0904-y     Document Type: Review

References (177)

1. Abelev GI, Perova SD, Khramkova NI, Postnikova ZA, Irlin IS. Production of embryonic alpha-globulin by the transplantable mouse hepatomas. Transplantation. 1963;1:174-80.
2. Tatarinov YuS. Detection of embryospecific alpha-globulin in serum of patients with primary liver cancer. In I-st All-Union Biochem Cong Abstr Book. 1963;2:274. Moscow-Leningrad.
3. Bergstrand CG, Czar B. Demonstration of a new protein fraction in serum from the human fetus. Scan J Clin Lab Invest. 1956;8:174-6.
4. Debruyne EN, Delange JR. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. Clin Chim Acta. 2008;395:19-26.
5. Tatarinov YS. Content of embryo-specific alpha-globulin in the blood serum of human fetus, newborns and adults. Vorp Med Khim. 1965;11:20-4.
6. Abelev GI. Alpha-fetoprotein in ontogenesis and its association with malignant tumors. Adv Cancer Res. 1971;14:295-358.
7. Ruoslahti E, Seppala M. Alpha-fetoprotein in cancer and fetal development. Adv Cancer Res. 1979;29:275-346.
8. Gitlin D, Boesman M. Sites of serum alpha-fetoprotein synthesis in the human and in the rat. J Clin Invest. 1967;46:1010-6.
9. Terentiev AA. Comparative studies of physico-chemical properties of human, bovine and sheep embryo-specific alpha-globulins. Proc ASMU 1968; XVI:336-41. Astrakhan.
10. Terentiev AA. Comparative study of fetuin and bovine embryo-specific alpha-globulin. Bull Exp Biol Med. 1969;7:42-5.
11. Kithier K, Masopust J, Rádl J. Fetal alpha-globulin of bone serum differing from fetuin. Biochim Biophys Acta. 1968;160:135-7.
12. Nishi S, Watabe H, Hirai H. Production of antibody to homologous alpha-fetoprotein in rabbits, rats and horses by immunization with human alpha-fetoprotein. J Immunol. 1967;109:957-60.
13. Nishi S, Watabe H, Hirai H. Species cross-reaction of alpha-fetoprotein and break down of the tolerance to alpha-fetoprotein by immunization with heterologous alpha-fetoprotein. Tumor Res. 1973;8:17-22.
14. Ruoslahti E, Seppala M. Studies of carcino-fetal proteinsIII. Development of radio-immunoassay for alpha-fetoprotein. Demonstration of alpha-fetoprotein in serum of healthy human adults. Intern J Cancer. 1971;8:374-83.
15. Ruoslahti E, Seppala M. α-Foetoprotein in normal human serum. Nature. 1972;235:161-2.
16. Deutsch HF. Chemistry and biology of alpha-fetoprotein. Adv Cancer Res. 1991;56:253-312.
17. Mizejewski GJ. The phylogeny of alpha-fetoprotein in vertebrates: survey of biochemical and physiological data. Crit Rev Eucaryot Gene Expr. 1995;5:281-316.
18. Mizejewski GJ. Alpha-fetoprotein structure and function: relevance to isoforms, epitopes and conformational variants. Exp Biol Med. 2001;226:377-408.
19. Terentiev AA, Moldogazieva NT. Structural and functional mapping of alpha-fetoprotein. Biochemistry (Mosc). 2006;71:120-32.
20. Lutsenko SV, Feldman NB, Finakova GV, Gukasova NV, Petukhov SV, Posypanova GA, et al. Study of antitumor activity of alpha-fetoprotein and epidermal growth factor conjugates in vitro and in vivo. Tumor Biol. 2000;21:367-74.
21. Godovannyi AV, Vorontsov EA, Gukasova NV, Pozdnyakova NV, Vasilenko EA, Yabbarov NG, et al. Targeted delivery of paclitaxel-loaded recombinant alpha-fetoprotein fragment-conjugated nanoparticles to tumor cells. Dokl Biochem Biophys. 2011;439:158-60.
22. Morinaga T, Sakai M, Wegmann TG, Namaoki T. Primary structure of human alpha-fetoprotein and its mRNA. Proc Natl Acad Sci U S A. 1983;80:4604-8.
23. Pucci P, Siliciano R, Malorni A, Marino G, Tecce MF, Ceccarini C, et al. Human alpha-fetoprotein primary structure: a mass spectrometric study. Biochemistry. 1991;30:5061-6.
24. Dudich I, Tokhtamysheva N, Semenkova L, Dudich E, Hellman Y, Korpela T. Isolation and structural and functional characterization of two stable peptic fragments of human alpha-fetoprotein. Biochemistry. 1999;38:10406-14.
25. Song Y-H, Naumova AK, Liebhaber SA, Cooke NE. Physical and meiotic mapping of the region of human chromosome 4q11-q13 encompassing the vitamin D-binding protein DBP/Gc-globulin and albumin multigene cluster. Genome Res. 1999;9:581-7.
26. Beatie WG, Dugaiczyk A. Structure and evolution of human alpha-fetoprotein deduced from partial sequence of cloned cDNA. Gene. 1982;20:415-22.
27. Ruoslahti E, Terry WD. Alpha-fetoprotein and serum albumin show sequence homology. Nature. 1976;260:804-5.
28. Cooke NE, David EV. Serum vitamin-D-binding protein is a third member of the albumin and alpha-fetoprotein gene family. J Clin Invest. 1985;76:2420-4.
29. Lichtenstein HS, Lyons DE, Wurfer MM, Johnson DA, MacGinley MD, Leidli JC, et al. Afamin is a new member of the albumin, alpha-fetoprotein and vitamin D-binding protein gene family. J Biol Chem. 1994;269:18149-54.
30. Terentiev AA. Structural prerequisition for participation of alpha-fetoprotein and transforming growth factor (TGF-beta) in cell cycle regulation. Med Immunol. 2004;6:256.
31. Luft AJ, Loscheider FL. Structural analysis of human and bovine α-fetoprotein by electron microscopy, image processing and circular dichroism. Biochemistry. 1983;22:5971-8.
32. He X-M, Carter D. Atomic structure and chemistry of human serum albumin. Nature. 1992;358:209-15.
33. Zizkovsky V, Strop P, Korcakova J, Havranova M, Mikes F. Fluorescence spectroscopy, fluorescence polarization and circular dichroism in studies of pH-dependent changes in the alpha-fetoprotein molecule. Ann N Y Acad Sci. 1983;417:49-56.
34. Barker ME. Evolution of alpha-fetoprotein: sequence comparisons among AFP species and with albumin species. Tumor Biol. 1988;9:123-36.
35. Gorin MB, Cooper DL, Eiferman F, van de Rijn P, Tilghman SM. The evolution of alpha-fetoprotein and albumin: 1 a comparison of the primary amino acid sequences of mammalian alpha-fetoprotein and albumin. J Biol Chem. 1981;256:1954-9.
36. Valette G, Vranckx R, Martin M-E, Benassayag C, Nunez EA. Conformational changes in rodent and human alpha-fetoprotein: influence of fatty acids. Biochim Biophys Acta. 1989;997:302-12.
37. Haourigui M, Thobie N, Martin M-E, Benassayag C, Nunez EA. In vivo transient rise in plasma free acids alters the functional properties of alpha-fetoprotein. Biochim Biophys Acta. 1992;1125:157-65.
38. Festin SM, Bennett JA, Fletcher PW, Jacobson HI, Shaye DD, Andersen TT. The recombinant third domain of human alpha-fetoprotein retains the antiestrothophic activity found in the full-length molecule. Biochim Biophys Acta. 1999;1427:307-14.
39. Carreres G, Dauphinee MJ, Eisele LE, MacColl R, Mizejewski GJ. Anti-prostate cancer and anti-breast cancer activities of two peptides derived from alpha-fetoprotein. Anticancer Res. 2002;22:2817-20.
40. Uversky VN, Kirkitadze MD, Narizhneva NV, Potekhin SA, Tomashevsky AY. Structural properties of alpha-fetoprotein from human cord serum: the protein molecule at low pH possesses all the properties of the molten globule. FEBS Letts. 1995;364:165-7.
41. Uversky VN, Narizhneva NV, Ivanova TV, Tomashevski AY. Rigidity of human alpha-fetoprotein tertiary structure is under ligand control. Biochemistry. 1997;36:13638-45.
42. Uversky VN, Narizhneva NV, Ivanova TV, Kirkitadze MD, Tomashevsky AY. Ligand-free form of human alpha-fetoprotein: evidence for the molten globule state. FEBS Letts. 1997;410:280-4.
43. Taketa K. Characterization of sugar chain structures of human AFP by lectin affinity electrophoresis. Electrophoresis. 1998;19:1774-9.
44. Breborowich J. Microheterogeneity of human alpha-fetoprotein. Tumor Biol. 1988;9:3-14.
45. Krivonosov SK, Zorin NA, Ionova NK, Terentiev AA, Tatarinov YS. Interaction of pregnancy-associated proteins with hemagglutinin and concanavalin A. Byul Eksp Biol Med. 1985;5:568-71.
46. Zorin NA, Krivonosov SK, Zorina RM, Terentiev AA, Ionova NK. Competitive inhibition of interactions between phytohemaglutinin A and blood serum glycoproteins by carbohydrates. Vopr Med Khim. 1986;32:96-8.
47. Aoyagi Y, Saitoh A, Suzuki Y, Igarashi K, Oguro M, Yokota T, et al. Fucosylation index of alpha-fetoprotein, a possible aid in the early recognition of hepatocellular carcinoma in patients with cirrhosis. Hepatology. 1993;17:50-2.
48. Seta N, Gayno S, Jezequel-Guer M, Toueg ML, Erlinger S, Durand G. Sequential study of serum glycoprotein fucosylation in acute hepatitis. J Hepatol. 1997;26:265-71.
49. Taketa K, Ichikawa E, Sakuda H, Iwamasa T, Hayakawa M, Taga H, et al. Lectin reactivity of alpha-fetoprotein in a case of renal cell carcinoma. Tumor Biol. 1989;10:275-80.
50. Taketa K, Fujii Y, Taga H. Characterization of E-PHA-reactive alpha-fetoprotein isoforms by two-dimensional lectin affinity electrophoresis. Electrophoresis. 1993;14:1333-7.
51. Shimizu K, Katoh H, Yamashita F, Tanaka M, Tanikawa K, Taketa K, et al. Comparison of carbohydrate structures of serum alpha-fetoprotein by sequential glycosidase digestion and lectin affinity electrophoresis. Clin Chim Acta. 1996;254:23-40.
52. Taketa K. Multimodal application of lectin affinity electrophoresis of alpha-fetoprotein. Electrophoresis. 1998;19:1774-9.
53. Parmelee DC, Evenson MA, Deutsch HF. The presence of fatty acids in human alpha-fetoprotein. J Biol Chem. 1978;253:2114-9.
54. Berde CB, Nagai M, Deutsch HF. Human alpha-fetoprotein. Fluorescence studies on binding and proximity relationships for fatty acids and bilirubin. J Biol Chem. 1979;254:12609-14.
55. Hsia JC, Er JS, Tan CT, Ester T, Ruoslahti E. α-Fetoprotein binding specificity for arachidonate, bilirubin, docosahexaenoate and palmitate. J Biol Chem. 1980;255:4224-7.
56. Nagai M, Becker JD, Deutsch HF. The fatty acid levels in rat alpha-fetoprotein derived from fetuses, pregnancy and hepatoma sera. Oncodev Biol Med. 1982;3:343-50.
57. Iturralde M, Alava MA, Gonzalez B, Anel A, Pineiro A. Effect of AFP and albumin on the uptake of polyunsaturated fatty acids by rat hepatoma cells and fetal rat hepatocytes. Biochim Biophys Acta. 1991;1086:81-8.
58. Aussel C, Negrel L. Effect of AFP on arachidonic acid metabolism in the preadipocyte cell line OB-17. Prostaglandins Leukotriene Med. 1986;21:69-76.
59. Ruoslahti E, Ester T, Seppala M. Binding of bilirubin by bovine and human alpha-fetoprotein. Biochim Biophys Acta. 1979;578:511-9.
60. Aoyagi Y, Ikenaka T, Ichida F. Alpha-fetoprotein as a carrier protein in plasma and its bilirubin-binding ability. Cancer Res. 1979;39:3571-4.
61. Aoyagi Y, Ikenaka T, Ishida F. Copper (II)-binding ability of human alpha-fetoprotein. Cancer Res. 1978;38:3483-6.
62. Birkenmeier G, Usbeck E, Saro L, Kopperschlager G. Triazine dye binding of human alpha-fetoprotein and albumin. J Chromatogr. 1983;265:27-35.
63. Ruiz-Gutierrez V, Moreno R, Moreda W, Copado MA, Rodriguez-Burgoz A. Detection of squalene in alpha-fetoprotein and fetal serum albumin from bovine. J Prot Chem. 2001;20:19-23.
64. Soloff MS, Swartz SK, Pearlmutter F, Kithier K. Binding of 17-β-estradiol by variants of alpha-fetoprotein in rat amniotic fluid. Biochim Biophys Acta. 1972;427:644-51.
65. Uriel J, de Nechaut B, Dupiers M. Estrogen-binding properties of rat, mouse and man fetospecific serum protein. Demonstration by immuno- autoradiographic methods. Biochem Biophys Res Commun. 1972;46:1175-80.
66. Uriel J, Bouillon D, Dupiers M. Affinity chromatography of human, rat and mouse alpha-fetoprotein on estradiol-sepharose adsorbents. FEBS Lett. 1975;53:305-8.
67. Uriel J, Bouillon D, Aussel C, Dupiers M. Alpha-fetoprotein: the major high affinity estrogen binder in rat uterine cytosols. Proc Natl Acad Sci USA. 1976;75:1452-6.
68. Nishi S, Matsue H, Yoshida H, Yamamoto R, Sakai M. Localization of estrogen-binding site of alpha-fetoprotein in chimeric human-rat proteins. Proc Natl Acad Sci USA. 1991;88:3102-5.
69. Milligan SR, Khan O, Nash M. Competitive binding of xenobiotic oestrogens to rat alpha-fetoprotein and sex steroid binding proteins in human and rainbow trout (Oncorhynchus mykiss) plasma. J Comp Endocrinol. 1998;112:89-95.
70. Terentiev AA, Moldogazieva NT, Tagirova AK, Tatarinov YS. Affinity chromatography of human alpha-fetoprotein on immobilized estrogens. Byul Eksp Biol Med. 1988;4:422-4.
71. Terentiev AA, Moldogazieva NT, Tagirova AK, Tatarinov YS. Competitive affinity chromatography of human alpha-fetoprotein on immobilized diethylstilbestrol. Byul Eksp Biol Med. 1990;5:438-40.
72. Tatarinov YS, Terentiev AA, Moldogazieva NT, Tagirova AK. Human alpha-fetoprotein and its purification by chromatography on immobilized estrogens. Tumor Biol. 1991;12:125-30.
73. Terentiev AA, Moldogazieva NT, Tagirova AK, Tatarinov YS. Affinity chromatography of rodent alpha-fetoprotein on immobilized diethylstilbestrol. Byul Eksp Biol Med. 1992;6:588-90.
74. Terentiev AA, Moldogazieva NT, Levtsova OV, Maximenko D, Borozdenko D, Shaitan KV. Modeling of three-dimensional structure of human alpha-fetoprotein complexed with diethylstilbestrol: docking and molecular dynamics simulation study. J Bioinform Comput Biol. 2012;10:1241012.
75. Lu CY, Changelian PS, Unanue ER. Alpha-fetoprotein inhibits macrophage expression of Ia antigens. J Immunol. 1984;132:1722-7.
76. Atemezem A, Mbemba E, Marfaing R, Vaysse J, Pontet M, Saffar L, et al. Human alpha-fetoprotein binds to primary macrophages. Biochem Biophys Res Commun. 2002;296:507.
77. Peck AB, Murgita RA, Wigzell H. Cellular and genetic restrictions in the immunoregulatory activity of α-fetoprotein. III. Role of the MLC-stimulating cell of α-fetoprotein induced suppression of T cell-mediated cytotoxicity. J Immunol. 1982;128:1134-40.
78. Cohen BL, Orn A, Gronvik K-O, Gidlund M, Wigzell H, Murgita RA. Suppression by alpha-fetoprotein of murine natural killer cell activity stimulated in vitro and in vivo by interferon and interleukin 2. Scand J Immunol. 1986;23:211-23.
79. Yachnin S. Demonstration of the inhibitory effect of human AFP on in vitro transformation of human lymphocytes. Proc Nat Acad Sci U S A. 1976;73:2857-60.
80. Yachnin S. The immunosuppressive properties of α-fetoprotein: a brief overview. Ann N Y Acad Sci. 1983;417:105-7.
81. Matsuura E, Kang Y, Katikawa H, Ogata P, Kotani T, Ohtaki S, et al. Modulation of T-cell function by alpha-fetoprotein. An in vivo study on porcine thyroid peroxidase induced experimental autoimmune thyroiditis in transgenic mice producing human alpha-fetoprotein. Tumor Biol. 1999;20:162-71.
82. Alpert E, Dienstag JL, Sepersky S, Littman B, Rocklin R. Immunosupressive characteristic of human AFP: effect on tests of cell mediated immunity and induction of human suppressor cell. Immunol Commun. 1978;7:163-85.
83. Van Oers NS, Cohen BL, Murgita RA. Isolation and characterization of a distinct immunoregulatory isoform of alpha-fetoprotein produced by the normal fetus. J Exp Med. 1989;170:811-25.
84. Semeniuk DJ, Boismenu R, Tam J, Weissenhofer W, Murgita RA. Evidence that immunosuppression is an intrinsic property of the alpha-fetoprotein molecule. Adv Exp Mol Biol. 1995;383:255-69.
85. Irony-Tur-Sinai M, Grigoriadis N, Tsiantoulas D, Touloumi O, Abramsky O, Brenner T. Immunomodulation of EAE by alpha-fetoprotein involves elevation of immune cell apoptosis markers and the transcription factor FoxP3. J Neurol Sci. 2009;279:80-7.
86. Kang G, Matsuura E, Sakamoto T, Sakai M, Nishi B. Analysis of epitopes of mouse monoclonal antibodies against human alpha-fetoprotein. Tumor Biol. 2001;22:254-61.
87. Butterfield LH, Koh A, Meng W, Volhmer CM, Ribas A, Dissette V, et al. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. Cancer Res. 1999;59:3134-42.
88. Butterfield LH, Meng WS, Koh A, Vollmer CM, Ribas A, Dissette VB, et al. T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. J Immunol. 2001;166:5300-8.
89. Butterfield LH, Ribas A, Mena WS, Dissette VB, Amarnami S, Vu HT, et al. T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res. 2003;9:5902-8.
90. Butterfield LH, Ribas A, Dissette VB, Lee Y, Yang JQ, De la Rocha P, et al. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res. 2006;12:2817-25.
91. Liu Y, Daley S, Evdokimova VN, Zdobinski DD, Potter DM, Butterfield LH. Hierarchy of alpha fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer. J Immunol. 2006;177:712-21.
92. Butterfield LH. Recent advances in immunotherapy for hepatocellular cancer. Swiss Med WKLY. 2007;137:83-90.
93. Pardee AD, Butterfield LH. Immunotherapy of hepatocellular carcinoma: unique challenges and clinical opportunities. Oncoimmunol. 2012;1:48-50.
94. Thimme R, Neagu M, Boettler T, Neumann-Haefelin C, Kersting N, Geissler M, et al. Comprehensive analysis of the alpha-fetoprotein-specific CD8+ T-cell responses in patients with hepatocellular carcinoma. Hepatology. 2008;48:1821-33.
95. Alisa A, Ives A, Pathan AA, Navarrete CV, Williams R, Bertoletti A, et al. Analysis of CD4+ T-cell responses to a novel alpha-fetoprotein-derived epitope in hepatocellular carcinoma patients. Clin Cancer Res. 2005;11:6686-94.
96. Ayaru L, Pereira SP, Alisa A, Pathan AA, Williams R, Davidson B, et al. Unmasking of alpha-fetoprotein-specific CD4+ T-cell responses in hepatocellular carcinoma patients undergoing embolization. J Immunol. 2007;178:1914-22.
97. Alisa A, Bouswell S, Pathan AA, Ayaru L, Williams R, Behboudi S. Human CD4+ T-cells recognize an epitope within alpha-fetoprotein sequence and develop into TGF-producing CD4+ T- cells. J Immunol. 2008;180:5109-17.
98. Behboudi S, Alisa A, Boswell S, Anastassiou J, Pathan AA, Williams R. Expansion of anti-AFP Th1 and Tc1 responses in hepatocellular carcinoma occur in different stages of disease. Br J Cancer. 2010;102:748-53.
99. 13-19) induced expression of CD-95 (FAS, Apo-1). Tumor Biol. 2000;21(Suppl1):110.
100. Terentiev AA, Simonova AV, Arshinova SS, Kulakov VV, Bahus GO, Kudryavtseva EV, et al. Influence of peptide LDSYQCT (sequence 14-20 of human AFP) on proliferative activity of human lymphocytes. Tumor Biol. 2003;24 Suppl 1:54.
101. Terentiev AA, Simonova AV, Arshinova SS, Kulakov VV, Bahus GO, Pavlichenkov AV, et al. Influence of the human AFP-derived peptide LDSYQC(acm)T on proliferative and cytotoxic activity of peripheral blood lymphocytes. Immunologiya. 2004;5:279-81.
102. Salmasi JM, Kazimirski AN, Terentiev AA, Poryadin GV, Kudryavtseva EV, Tatarinov YS. LDSYQCT-peptide synthetic analogue of human alpha-fetoprotein (13-19) increases anti-proliferative effect of cytozar on the lymphocytes of chronic leukemia patients. Tumor Biol. 1999;20 Suppl 2:43.
103. Moldogazieva NT, Terentiev AA, Kazimirsky AN, Antonov MY, Shaitan KV. Conformational dynamics of human alpha-fetoprotein-derived heptapeptide LDSYQCT analogs. Biochemistry (Mosc). 2007;72:529-39.
104. 14-20. Biochemistry (Mosc). 2011;76:1321-36.
105. Moldogazieva NT, Terentiev AA, Antonov MY, Kazimirsky AN, Shaitan KV. Correlation between biological activity and conformational and dynamic properties of tetra- and pentapeptide fragments of fetoplacental proteins. Biochemistry (Mosc). 2012;77:469-84.
106. Leffert HI, Sell S. Alpha-fetoprotein biosynthesis during the growth cycle of differentiated fetal rat hepatocytes to primary monolayer culture. J Cell Biol. 1974;61:823-9.
107. Toder V, Bland M, Gold-Gefter L, Nebel J. The effect of alpha-fetoprotein on the growth of placental cells in vitro. Placenta. 1983;4:79-86.
108. Hamel S, Hoskin DW, Hooper DC, Murgita RA. Phenotype and function of bone marrow-derived T and non-T cells activated in vitro by alpha-fetoprotein. In: Mizejewski GJ, Jacobson HI, editors. Biological activities of alpha-fetoprotein. Florida: CRC; 1987. p. 167-77.
109. Wang XW, Xu B. Stimulation of tumor-cell growth by alpha-fetoprotein. Int J Cancer. 1998;75:596-9.
110. Wang XW, Xie H. Alpha-fetoprotein enhances the proliferation of human hepatoma cells in vitro. Life Sci. 1999;64:17-23.
111. Laderoute MP, Pilarski LM. Inhibition of apoptosis by alpha-fetoprotein (AFP) and role of AFP receptors in anti-cellular senescence. Anticancer Res. 1974;14:2429-38.
112. Shehata MA, Nosseir HR, Nagy HM, Farouk G. Cyclin dependent kinase inhibitor p27(kip1) expression and subcellular localization in relation to cell proliferation in heap to cellular carcinoma. Egypt J Immunol. 2006;13:115-30.
113. Mizejewski GJ, Vonnegut M, Jacobson HI. Estradiol-activated alpha-fetoprotein suppresses the uteroptropic response to estrogens. Proc Natl Acad Sci U S A. 1983;80:2733-7.
114. Allen SHG, Bennett JA, Mizejewski GJ, Andersen TT, Ferraris S, Jacobson HI. Purification of human alpha-fetoprotein from human cord serum with demonstration of its antiestrogenic activity. Biochim Biophys Acta. 1993;1202:135-42.
115. Jacobson HI, Thompson VD, Janerich DT. Multiple births and maternal risk of breast cancer. Amer J Epidemiol. 1989;129:865-73.
116. Jacobson HI, Bennett JA, Mizejewski GJ. Inhibition of estrogen-dependent breast cancer growth by a reaction product of alpha-fetoprotein and estradiol. Cancer Res. 1990;50:415-20.
117. Boismenn R, Semeniuk D, Murgita RA. Purification and characterization of human and mouse recombinant alpha-fetoprotein expressed in Echerichia coli. Protein Expres Purif. 1997;10:10-26.
118. Bennett JA, Semeniuk DJ, Jacobson HI, Murgita RA. Similarity between natural and recombinant human alpha-fetoprotein as inhibitors of estrogen-dependent breast cancer growth. Breast Cancer Res Treat. 1997;45:169-79.
119. Bennett JA, Zhu S, Pagano-Mirarchi A, Kellom TA, Jacobson HI. Alpha-fetoprotein derived from a human hepatoma prevents growth of estrogen-dependent human breast cancer xenografts. Clin Cancer Res. 1998;4:2877-84.
120. Mizejewski GJ, Dias JA, Hauer CR, Henrikson KP, Gierthy I. Alpha-fetoprotein derived synthetic peptides: assay from an estrogen-modifying regulatory segment. Mol Cell Endocrinol. 1996;118:15-33.
121. Vakharia D, Mizejewski GJ. Human alpha-fetoprotein peptides bind estrogen receptor and estradiol and suppress breast cancer. Breast Cancer Res Treat. 2000;63:41-52.
122. Eisele LE, Mesfin FB, Bennett JA, Andersen TT, Jacobson HI, Soldwedel H, et al. Studies of a growth inhibitory peptide derived from alpha-fetoprotein and some analogs. J Peptide Res. 2001;57:29-38.
123. Eisele LE, Mesfin FB, Bennett JA, Andersen TT, Jacobson HI, Soldwedel H, et al. Studies on analogs of a peptide derived from alpha-fetoprotein having antigrowth properties. J Peptide Res. 2001;57:539-46.
124. MacColl R, Eisele LE, Stack RF, Hauer C, Vakharia DD, Benno A, et al. Interrelationship among biological activity, disulphide bonds, secondary structure and metal ion binding for a chemically synthesized 34-amino-acid peptide derived from α-fetoprotein. Biochim Biophys Acta. 2001;1528:127-34.
125. Butterstein G, Morrison J, Mizejewski GJ. Effect of alpha-fetoprotein and derived peptides on insulin and estrogen-induced fetotoxicity. Fetal Diagn Ther. 2003;18:360-9.
126. Carerres G, Dauphinee MJ, Eisele LE, MacColl R, Mizejewski GJ. Anti-prostate cancer and anti-breast cancer activities of two peptides derived from alpha-fetoprotein. Anticancer Res. 2002;22:2817-20.
127. Mesfin FB, Bennett GA, Jacobson HI, Zhu S, Andersen TT. Alpha-fetoprotein-derived antiestrotrophic octapeptide. Biochim Biophys Acta. 2000;1501:33-43.
128. Mesfin FB, Andersen TT, Jacobson HI, Zhu S, Bennett GA. Development of a synthetic cyclized peptide derived from alpha-fetoprotein that prevents the growth of human breast cancer. J Peptide Res. 2001;58:246-56.
129. Hamsa A, Sarma MH, Sarma RH. Plausible interaction of an alpha-fetoprotein cyclopeptide with the G-protein coupled receptor model GPR30: docking study by molecular dynamics simulated annealing. J Biomol Struct Dyn. 2003;20:751-8.
130. Sierralta WD, Epunan MJ, Reyes JM, Valladares LE, Andersen TT, Bennett JA, et al. A peptide derived from alpha-fetoprotein inhibits the proliferation induced by estradiol in mammary tumor cells in culture. Oncol Rev. 2008;19:229-35.
131. Bennett JA, DeFreest L, Anaka I, Saadati H, Balulad S, Jacobson HI, et al. AFPep: an anti-breast cancer peptide that is orally active. Breast Cancer Res Treat. 2006;98:133-41.
132. Mizejewski GJ, MacColl R. Alpha-fetoprotein growth inhibitory peptides: potential leads for cancer therapeutics. Mol Cancer Ther. 2003;2:1243-55.
133. Mizejewski GJ. Alpha-fetoprotein (AFP)-derived peptides as epitopes for hepatoma immunotherapy: a commentary. Cancer Immunol Immunother. 2009;58:159-70.
134. Mizejewski GJ. Mapping of structure-function peptide sites on the human alpha-fetoprotein amino acid sequence. Atlas Genet Cytogenet Oncol Hematol. 2010;2:331-82.
135. Gabant P, Forrester L, Nicols J, Van Reeth T, De Mees C, Bajac B, et al. Alpha-fetoprotein, the major fetal serum protein, is not essential for embryonic development but is required for female fertility. Proc Natl Acad Sci U S A. 2002;99:12865-70.
136. Dohler KD. The pre- and postnatal influence of hormones and neurotransmitters on sexual differentiation of the mammalian hypothalamus. Int Rev Cytol. 1991;131:1-57.
137. De Mees C, Laes JF, Bakker J, Smitz J, Hennuy B, Van Vooren P, et al. Alpha-fetoprotein controls female fertility and prenatal development of the gonadotropin-releasing hormone pathway through an antiestrogenic action. Mol Cell Biol. 2006;26:2012-8.
138. Uriel J, Trojan J, Moro R, Pineiro A. Intracellular uptake of α-fetoprotein: a marker of neural differentiation. Ann N Y Acad Sci. 1983;417:321-9.
139. Villacampa MJ, Moro R, Naval J, Failly-Crepin C, Lampreave F, Uriel J. Alpha-fetoprotein receptors in a human breast cancer cell line. Biochem Biophys Res Commun. 1984;122:1322-7.
140. Naval J, Villacampa MJ, Goguel AF, Uriel J. Cell-type-specific receptors for alpha-fetoprotein in a mouse T-lymphoma cell line. Proc Natl Acad Sci U S A. 1986;82:3301-4.
141. Uriel J, Naval J, Laborda J. Alpha-Fetoprotein-mediated transfer of arachidonic acid into cultured cloned cells derived from a rat rhabdomyosarcoma. J Biol Chem. 1987;262:3579-85.
142. Torres JM, Laborda J, Naval J, Darracq N, Calvo M, Mishal Z, et al. Expression of alpha-fetoprotein receptors by human T-lymphocytes during blastic transformation. Mol Immunol. 1989;26:851-7.
143. Torres JM, Geuskens M, Uriel J. Activated human T lymphocytes express albumin binding proteins which cross-react with alpha-fetoprotein. Eur J Cell Biol. 1992;57:222-8.
144. Suzuki Y, Zeng CQY, Alpert E. Isolation and partial characterization of a specific alpha-fetoprotein receptor on human monocytes. J Clin Invest. 1992;90:1530-6.
145. Alava MA, Iturralde M, Lampreave F, Pineiro A. Specific uptake of alpha-fetoprotein and albumin by rat Morris 7777 hepatoma cells. Tumor Biol. 1999;20:52-64.
146. Moro R, Tamaoki T, Wegmann TJ, Longnecker BM, Laderoute MP. Monoclonal antibodies directed against a widespread oncofetal antigen: the alpha-fetoprotein receptor. Tumor Biol. 1993;14:116-30.
147. Lorenzo HG, Geuskens M, Macho A, Lachkar S, Verdiere-Sahuque M, Pineiro A, et al. Alpha-fetoprotein binding and uptake by primary cultures of human skeletal muscle. Tumour Biol. 1996;17:251-60.
148. Li MS, Li PF, Yang FY, He SP, Du GG, Li G. The intracellular mechanism of AFP promoting the proliferation of NIH 393 cells. Cell Res. 2002;12:151-6.
149. Newby D, Dalgliesh G, Lyall F, Aitken DA. Alpha-fetoprotein and alpha-fetoprotein receptor expression in the normal human placenta at term. Placenta. 2005;26:190-200.
150. Mizejewski GJ. Review of the putative cell-surface receptors for alpha-fetoprotein: identification of a candidate receptor protein family. Tumor Biol. 2011;32:241-58.
151. Mizejewski GJ. Review of the adenocarcinoma cell surface receptor for human alpha-fetoprotein; proposed identification of a widespread mucin as the tumor cell receptor. Tumor Biol. 2013;34:1317-36.
152. Li MS, Li PF, Du GG, Li G. The promoting molecular mechanism of alpha-fetoprotein on the growth of human hepatoma Bel7402 cell line. World J Gastroenterol. 2002;8:469-75.
153. Li MS, Li PF, Chen Q, Du GG, Li G. Alpha-fetoprotein stimulated the expression of some oncogenes in human hepatocellular carcinoma Bel7402 cells. World J Gastroenterol. 2004;10:819-24.
154. Li M-S, Ma Q-L, Chen Q, Liu X-H, Li P-F, Du G-G, et al. Alpha-fetoprotein triggers hepatoma cells escaping from immune surveillance through altering the expression of Fas/FasL and tumor necrosis factor related apoptosis-inducing ligand and its receptor of lymphocytes and liver cancer cells. World J Gastroenterol. 2005;11:2564-9.
155. Li M-S, Li H, Li C, Zhou S, Guo L, Liu H, et al. Alpha fetoprotein is a novel protein-binding partner for caspase-3 and blocks the apoptotic signaling pathway in human hepatoma cells. Int J Cancer. 2009;124:2845-54.
156. Li M-S, Li H, Li C, Guo L, Liu H, Zhou S, et al. Cytoplasmic alpha-fetoprotein functions as a co-repressor in RA-RAR signaling to promote the growth of human hepatoma Bel 7402 cells. Cancer Lett. 2009;285:190-9.
157. Li M-S, Li H, Li C, Wang S, Wei J, Liu Z, et al. Alpha-fetoprotein: a new member of intracellular signal molecules in regulation of the PI3K/AKT signaling in human hepatoma cell lines. Int J Cancer. 2011;128:524-32.
158. Goldstein NS, Blue DE, Hankin R, Hunter S, Bayati N, Silverman AL, et al. Serum alpha-fetoprotein levels in patients with chronic hepatitis C: relationships with serum alanine aminotransferase values, histologic activity index and hepatocyte MIB-I scores. Am J Clin Pathol. 1999;111:811-6.
159. Semenkova LN, Dudich EI, Dudich IV, Shingarova LN, Korobko VG. α-Fetoprotein as a TNF-resistance factor for human hepatocarcinoma cell line HepG2. Tumor Biol. 1997;18:30-40.
160. Dudich E, Semenkova L, Dudich I, Gorbatova E, Tokhtamisheva N, Tatulov E, et al. Alpha-fetoprotein causes apoptosis in tumor cells via a pathway independent of CD95, TNFR1 and TNFR2 through activation of caspase-3-like proteases. Eur J Biochem. 1999;266:750-61.
161. Semenkova L, Dudich E, Dudich I, Tokhtamisheva N, Tatulov E, Okruzhnov Y, et al. Alpha-fetoprotein positively regulates cytochrome c-mediated caspase activation and apoptosome complex formation. Eur J Biochem. 2003;270:4388-99.
162. Dudich E. MM-093, a recombinant human alpha-fetoprotein for the potential treatment of rheumatoid arthritis and other autoimmune diseases. Curr Opin Mol Ther. 2007;9:603-10.
163. Seppala M. Fetal pathophysiology of human alpha-fetoprotein. Ann NY Acad Sci. 1975;259:59-73.
164. Brock DJ, Scrimgeour JB, Nelson MM. Amniotic fluid alpha-fetoprotein measurements in the prenatal diagnosis of central nervous system disorders. Genetics. 1975;7:163-9.
165. Petropoulos C, Andrews G, Tamaoki T, Fausto N. Alpha-fetoprotein and albumin mRNA levels in liver regeneration and carcinogenesis. J Biol Chem. 1983;258:4901-6.
166. Won YS, Lee SW. Targeted retardation of hepatocarcinoma cells by specific replacement of alpha-fetoprotein RNA. J Biotechnol. 2007;129:614-9.
167. Zhang H, Bai ZL, Chen J, Wang Z, Li J. Alpha-fetoprotein-specific transfer factors downregulate alpha-fetoprotein expression and specifically induce apoptosis in Bel7402 alpha-fetoprotein-positive hepatocarcinoma cells. Hepatol Res. 2007;37:557-67.
168. Lee NP, Chen L, Lin MC, Tsang FH, Yeung C, Poon RT, et al. Proteomic expression signature distinguishes cancerous and nonmalignant tissues in hepatocellular carcinoma. J Proteome Res. 2009;8:1293-303.
169. Saito S, Ojima H, Ichikawa H, Hirohashi S, Kondo T. Molecular background of alpha-fetoprotein in liver cancer cells as revealed by global RNA expression analysis. Cancer Sci. 2008;99:2402-9.
170. Wang XY, Degos F, Dubois S. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol. 2006;37:1435-41.
171. Spangenberg HC, Thimme R, Blum HE. Serum markers of hepatocellular carcinoma. Semin Lver Dis. 2006;26:385-90.
172. Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, Saab S, et al. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol. 2008;23:1541-8.
173. Bertino G, Neri S, Bruno CM, Ardini AM, Calvagno GS, Malaguarnera M, et al. Diagnostic and prognostic value of alpha-fetoprotein, des-γ-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma. Minerva Med. 2011;102:363-71.
174. Bertino G, Ardini A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Semin Oncol. 2012;39:410-33.
175. Sharapova OA, Pozdniakova NV, Laurinavichiute DK, Iurkova MS, Posypanova GA, Andronova SM, et al. Purification and characterization of recombinant human alpha-fetoprotein fragment, corresponding to the C-terminal structural domain. Bioorg Khim. 2010;36:760-8.
176. Sharapova OA, Yurkova MS, Laurinavichyute DK, Andronova SM, Fedorov AN, Severin SE, et al. Efficient refolding of a hydrophobic protein with multiple S-S bonds by on-resin immobilized metal affinity chromatography. J Chromat A. 2011;1218:5115-9.
177. Mizejewski GJ, Mirowski M, Garnuszek P, Maurin M, Cohen BD, Poiesz BJ, et al. Targeted delivery of anti-cancer growth inhibitory peptides derived from human α-fetoprotein: review of an International Multi-Center Collaborative Study. J Drug Target. 2010;18:575-88.